Brooks O'Neil

Chris Kallos

Joshua Jennings

Ross Osborn

Ryan Zimmerman

Eric Anderson

John Hester

Josh Jennings

Lyanne Harrison

Matthew Park

Phillip Dantoin

Samantha

- **AVITA Medical** announced that **Australia’s Medical Services Advisory Committee (MSAC)** has recommended amendments to the Medicare Benefits Schedule (MBS) to include the use of **RECELL** for treating severe acute burn wounds in adults and children.  **[1762303_ba31532a679742fe8c9c2e82c506bd95_0]** 
- MSAC recognized RECELL as **safe and effective**, providing benefits such as improved healing, donor site sparing, and reduced hospital stays.  **[1762303_ba31532a679742fe8c9c2e82c506bd95_0]** 
- The committee concluded that RECELL offers **superior outcomes in donor site sparing** and reduces the need for additional grafting procedures compared to traditional autologous skin grafting.  **[1762303_ba31532a679742fe8c9c2e82c506bd95_0]** 
- RECELL is also acknowledged for its ability to **shorten hospital stays**, ease patient pain, and minimize scarring.  **[1762303_ba31532a679742fe8c9c2e82c506bd95_0]**

AVITA Medical Announces Australian MSAC Recommendation for RECELL in Burn Treatment

- **AVITA Medical's RECELL System** is now eligible for **New Technology Add-on Payment (NTAP) reimbursement from the Centers for Medicare & Medicaid Services (CMS)** for treating acute, non-burn trauma and surgical full-thickness wounds in U.S. hospitals.  **[1762303_65bb8995c6294d4ea6d99300177d03c2_1]** 
- Effective **October 1, 2025**, this NTAP designation allows hospitals to receive **up to $4,875 in supplemental reimbursement per case** in addition to standard CMS payments.  **[1762303_65bb8995c6294d4ea6d99300177d03c2_0]** **[1762303_65bb8995c6294d4ea6d99300177d03c2_1]** 
- The NTAP aims to **ease financial barriers** and support broader use of RECELL, and will remain in effect through **September 30, 2026**.  **[1762303_65bb8995c6294d4ea6d99300177d03c2_0]** **[1762303_65bb8995c6294d4ea6d99300177d03c2_1]**

AVITA Medical's RECELL Receives CMS New Technology Add-on Payment

- AVITA Medical, Inc. (RCEL) has received the **CE Mark** under the European Union Medical Device Regulation (EU MDR) for **RECELL GO**, which permits its commercialization in Europe and other markets that recognize the CE Mark.  **[1762303_76099baff79147368bf3d488c729aa9c_0]** 
- RECELL GO is a point-of-care device used by healthcare professionals to prepare a suspension of a patient’s own skin cells (Spray-On Skin™ Cells) to promote healing in burns and traumatic or surgical wounds.  **[1762303_76099baff79147368bf3d488c729aa9c_0]** 
- Data presented at the 2025 European Burns Association Congress demonstrated that adults with deep partial-thickness burns treated with RECELL experienced a **36% reduction in hospital stays** compared with traditional grafting.  **[1762303_76099baff79147368bf3d488c729aa9c_0]** 
- AVITA Medical will begin commercialization of RECELL GO in select European countries, including **Germany, Italy, and the United Kingdom**.  **[1762303_76099baff79147368bf3d488c729aa9c_0]**

AVITA Medical Receives CE Mark for RECELL GO, Enabling European Commercialization

AVITA Medical (RCEL)